NCT05860374

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Status unknown EARLY_PHASE1 Last updated 16 May 2023

What this trial tests

EARLY_PHASE1 trial testing Recombinant oncolytic herpes simplex virus type 1 (R130) in Sarcoma in 20 participants. Status unknown.

Timeline

2 March 2023

Primary endpoint
2 March 2025

2 March 2026

Quick facts

Lead sponsor	Shanghai Yunying Medical Technology
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	2 March 2023
Primary completion	2 March 2025
Estimated completion	2 March 2026
Sites	1 location across China

Drugs / interventions tested

• Recombinant oncolytic herpes simplex virus type 1 (R130) — full drug profile →

Conditions studied

• Sarcoma — all drugs for Sarcoma →
• Carcinoma — all drugs for Carcinoma →
• Breast Cancer — all drugs for Breast Cancer →
• Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Shanghai Yunying Medical Technology — full company profile →

Who can join

Adults 18 to 75, any sex, with Sarcoma or Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.
   Mantooth SM, Abdou Y, Saez-Ibañez AR, Upadhaya S, et al · · 2024 · cited 13× · PMID 38803496 · DOI 10.3389/fimmu.2024.1385484
2. Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.
   Nia GE, Nikpayam E, Farrokhi M, Bolhassani A, et al · · 2024 · cited 7× · PMID 38596310 · DOI 10.1016/j.omton.2024.200788
3. Oncolytic HSV and cancer drug interactions: Current clinical status and future directions.
   Vázquez-Arreguín K, Rivera-Caraballo KA, Ventarapragada D, Chiocca EA, et al · · 2025 · cited 6× · PMID 40702727 · DOI 10.1016/j.ymthe.2025.07.034
4. Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses.
   Thoidingjam S, Bhatnagar AR, Sriramulu S, Siddiqui F, et al · · 2024 · cited 6× · PMID 39337402 · DOI 10.3390/ijms25189912
5. Research progress on mechanisms of tumor immune microenvironment and gastrointestinal resistance to immunotherapy: mini review.
   Zhang Z, Wu Y. · · 2025 · cited 4× · PMID 40787471 · DOI 10.3389/fimmu.2025.1641518
6. Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry.
   Dong W, Luo Y, He D, Zhang M, et al · · 2024 · cited 4× · PMID 39430750 · DOI 10.3389/fimmu.2024.1473288
7. Viral warriors: Unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy.
   Ghavimi R, Rahimian L, Mohammadi M, Dutta O, et al · · 2025 · cited 3× · PMID 41438130 · DOI 10.1016/j.omton.2025.201100
8. Oncolytic viruses: advanced strategies in cancer therapy.
   Xiao D, Zhang H, Liu Y, Li Y, et al · · 2026 · cited 2× · PMID 41639062 · DOI 10.1038/s41392-025-02343-3